Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome

Last updated: November 20, 2016
Sponsor: Jingqing Hu
Overall Status: Trial Status Unknown

Phase

N/A

Condition

Coronary Artery Disease

Atherosclerosis

Chest Pain

Treatment

N/A

Clinical Study ID

NCT02967718
2014CB542903
  • Ages 35-85
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Coronary heart disease is still the major cause of death in China. Chinese medicine plays more and more important role in CHD prevention and treatment. Phlegm and blood stasis are its major pathological basis. Based on that, the investigator aims to evaluate the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method so as to guide the clinical treatment of CHD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy or metabolism syndrome people

  • Clinical diagnosis of CHD stable stage or acute coronary disease or CHD heart failure

Exclusion

Exclusion Criteria:

  • Any inflammation, fever, trauma, burn or operation within 1 week

  • Obstructive pulmonary disease

  • Cerebral vascular disease

  • Severe renal or hepatic dysfunction

  • Malignant neoplasms

  • Hematopoietic system disease

  • Sever mental disease

Study Design

Total Participants: 13000
Study Start date:
September 01, 2016
Estimated Completion Date:
December 31, 2017

Study Description

Coronary heart disease (CHD) is a major cause of myocardial infarct (MI) and death induced by atherosclerosis or coronary artery spasm. Despite improvements in interventional and pharmacological therapy for acute MI, the mortality early after AMI remains high. Nowadays, as our life quality develops and dietary structure changes, the morbidity of hyperlipidemia dramatically increased. Based on the Chinese medicine, hyperlipidemia belongs to phlegm and it's the basis of atherosclerosis, blood-stasis is the pathological basis of ischemia. Therefore, the investigator proposes that phlegm and blood-stasis syndrome is the main differentiation on CHD. Based on that, the investigator prospectively and retrospectively explores the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method.It will provide evidence and guidance to the future clinical treatment using Chinese medicine.

Connect with a study center

  • The First Integrative Hospital of Beijing

    Beijin, Beijing
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.